G. Lu

发表

Formation of Factors IXa and Xa by the Extrinsic Pathway

Sriram Krishnaswamy, G. Broze, S. Krishnaswamy, 2004, Journal of Biological Chemistry.

A phase 2 PK/PD study of andexanet alfa for reversal of rivaroxaban and edoxaban anticoagulation in healthy volunteers.

J. Leeds, P. Conley, M. Karbarz, 2020, Blood advances.

Safety, pharmacokinetics, and reversal of apixaban anticoagulation with andexanet alfa.

J. Leeds, P. Conley, M. Karbarz, 2017, Blood advances.

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial Demonstrating Reversal of Edoxaban-Induced Anticoagulation in Healthy Subjects By Andexanet Alfa (PRT064445), a Universal Antidote for Factor Xa (fXa) Inhibitors

S. Connolly, J. Leeds, P. Conley, 2014 .

455: REVERSAL OF FACTOR XA INHIBITORS-INDUCED ANTICOAGULATION IN HEALTHY SUBJECTS BY ANDEXANET ALFA

S. Connolly, J. Leeds, P. Conley, 2014 .

Andexanet versus prothrombin complex concentrates: Differences in reversal of factor Xa inhibitors in in vitro thrombin generation

P. Conley, K. Bui, J. Curnutte, 2020, Research and practice in thrombosis and haemostasis.

Andexanet alfa effectively reverses edoxaban anticoagulation effects and associated bleeding in a rabbit acute hemorrhage model

J. Leeds, P. Conley, P. Pratikhya, 2018, PloS one.

Recombinant Antidote for Reversal of Anticoagulation by Factor Xa Inhibitors.

D. Phillips, S. Hollenbach, U. Sinha, 2008 .

Abstract 12420: Reversal of Low Molecular Weight Heparin and Fondaparinux by a Recombinant Antidote (r-Antidote, PRT064445)

P. Conley, P. Luan, D. Phillips, 2010 .

Comparison of reversal activity and mechanism of action of UHRA, andexanet, and PER977 on heparin and oral FXa inhibitors.

C. Haynes, A. Creagh, P. Conley, 2018, Blood advances.

Measuring residual anti‐Xa activity of direct factor Xa inhibitors after reversal with andexanet alfa

P. Conley, F. Depasse, G. Lu, 2021, International journal of laboratory hematology.

ANDEXANET ALFA FOR ACUTE BLEEDING DURING TREATMENT WITH ENOXAPARIN

S. Connolly, J. Eikelboom, T. Milling, 2021 .

Effects of Andexanet Alfa on Thrombin Generation in Bleeding Associated with Factor Xa Inhibitors

S. Connolly, J. Eikelboom, P. Verhamme, 2019, Blood.

Reversal of Heparin-Induced Anticoagulation By Andexanet Alfa, a Universal Antidote for Factor Xa Inhibitors

P. Conley, J. Curnutte, G. Lu, 2015 .

Abstract 14657: Andexanet-alfa and PER977 (Arapazine) Correct Blood Loss in a Rabbit Liver Laceration Model - Only Andexanet Reverses Markers of fXa-mediated Anticoagulation

P. Conley, P. Pratikhya, A. Pandey, 2014 .

ANNEXATM-R: A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, DEMONSTRATING REVERSAL OF RIVAROXABAN-INDUCED ANTICOAGULATION IN OLDER SUBJECTS BY ANDEXANET ALFA (PRT064445), A UNIVERSAL ANTIDOTE FOR FACTOR XA (FXA) INHIBITORS

S. Connolly, J. Leeds, P. Conley, 2015 .

Abstract 18218: In Vitro Characterization of Andexanet Alfa (PRT064445), a Specific fXa Inhibitor Antidote versus Aripazine (PER977), a Non-specific Reversal Agent

L. Jennings, P. Conley, A. Pandey, 2014 .

PRT064445 but Not Recombinant Fviia Reverses Rivaroxaban Induced Anticoagulation As Measured by Reduction in Blood Loss in a Rabbit Liver Laceration Model

S. Hollenbach, U. Sinha, G. Lu, 2012 .

reversal of enoxaparin-induced anticoagulation in healthy subjects by andexanet alfa (prt064445), an antidote for direct and indirect fxa inhibitors—a phase 2 randomized, double-blind, placebo-controlled trial : Coa01

S. Connolly, J. Leeds, P. Conley, 2014 .

Abstract 10: Randomized, Double-Blind, Placebo-Controlled Single Ascending Dose Pharmacokinetic and Pharmacodynamic Study of PRT064445, a Universal Antidote for Factor Xa Inhibitors

M. Karbarz, M. Crowther, J. Curnutte, 2013 .

314 Reversal of Betrixaban-Induced Anticoagulation in Healthy Volunteers by Andexanet Alfa

S. Connolly, J. Leeds, P. Conley, 2017 .

Reversal of Betrixaban-Induced Anticoagulation in Healthy Volunteers By Andexanet Alfa

S. Connolly, J. Leeds, P. Conley, 2016 .

Andexanet Alfa, a Universal Antidote Under Development for Factor Xa Inhibitors, Reverses Rivaroxaban-Induced Inhibition of Thrombin Generation Initiated By the Intrinsic Coagulation Pathway Independent of TFPI

P. Conley, J. Curnutte, G. Lu, 2016 .

Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors.

S. Connolly, B. Wiens, J. Eikelboom, 2016, The New England journal of medicine.

Using engineered 6-O-sulfotransferase to improve the synthesis of anticoagulant heparin.

Zhenqing Zhang, L. Pedersen, Yongmei Xu, 2020, Organic & biomolecular chemistry.

Reversal of Apixaban and Rivaroxaban Anticoagulation by Andexanet Alfa in ANNEXA-A and ANNEXA-R as Assessed by Non-Tissue Factor-Initiated Thrombin Generation Independent of Tissue Factor Pathway Inhibitor

P. Conley, J. Curnutte, G. Lu, 2018, EMJ Cardiology.

Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors

A. Demchuk, S. Connolly, J. López-Sendón, 2019, The New England journal of medicine.

Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity.

S. Connolly, B. Wiens, J. Leeds, 2015, The New England journal of medicine.

Preclinical safety and efficacy of andexanet alfa in animal models

P. Conley, J. Curnutte, S. Hollenbach, 2017, Journal of thrombosis and haemostasis : JTH.

A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa

P. Conley, P. Luan, M. Karbarz, 2013, Nature Medicine.

Effect of Andexanet-TFPI Interaction on in Vitro Thrombin Formation and Coagulation Markers in the TF-Pathway

P. Conley, J. Curnutte, G. Lu, 2017 .

An Anticoagulant RNA Aptamer That Inhibits Proteinase-Cofactor Interactions within Prothrombinase*

B. Sullenger, C. Rusconi, J. Layzer, 2009, The Journal of Biological Chemistry.

The Affinity of Protein C for the Thrombin·Thrombomodulin Complex Is Determined in a Primary Way by Active Site-dependent Interactions*

S. Krishnaswamy, G. Lu, S. Chhum, 2005, Journal of Biological Chemistry.

Andexanet Alfa for Specific Anticoagulation Reversal in Patients with Acute Bleeding during Treatment with Edoxaban

S. Connolly, J. Eikelboom, T. Milling, 2022, Thrombosis and Haemostasis.